preview upsid look like
neuro launch ultomiri uptak
neuro franchis possibl sourc upsid recent
channel check alxn soliri continu indic steadi growth
high intent treat among relapsed/refractori gmg popul
soliri nmosd pdufa date set june strong efficaci high unmet
need suggest second soliri neuro launch may also offer upsid
consensu given manag account
modest initi contribut year
rate
think alxn guidanc beatabl coupl strong earli
consensus/guid creep current consensu vs
upper end alxn guidanc current project
revenu aggress uptak neuro franchis
near term bit consensu oper margin expans
translat non-gaap ep versu consensu
mid-point guidanc alexion report first quarter result
confer id
model chang catalyst adjust project
neuro franchis base recent manag disclosur around gmg
launch confirm on-going channel check suggest upsid
gmg potenti upsid expect first year
forthcom nmo launch ep versu
previous nt event includ fcrn data waiha june
nmo pdufa septemb soliri eu patent hear risk
thesi includ commerci regulatori ip clinic headwind
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
alexion biotechnolog compani focus research
develop commerci therapeut rare diseas
alexion drug soliri use treat patient complement
mediat disord product includ strensiq
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
abl convert major soliri patient prior
launch biosimilar continu strength gmg launch
posit nmo data increas pipelin valu
unabl convert major soliri patient
prior launch biosimilar eu/row weak gmg
trend failur nmo decreas pipelin valu
 close
cs consensu ahead guidanc
continu see manag guidanc rel conserv
current ahead consensu top-line driven mostli faster uptak
neuro franchis oper margin ep
alexion report first quarter result thursday april earn
call dial-in et usa
million except ep
incom tax non-gaap
provis incom tax
figur cs/consensu ahead alxn guidanc
million except ep
examin near long term outlook soliri
gmg momentum continu near-term compani recent disclos
 day march gmg patient soliri march
continu strong trend launch manag indic still see
net patient ad per week believ pace could continu
next coupl quarter least channel check suggest physician
overal favor experi soliri reason access reimburs
high intent treat remain relapsed/refractori patient
charl martineau univers toronto figur soliri gmg us histor project new patients/revenu
pt soliri
see continu upsid case rel consensu near-term
next year anticip higher penetr wareh address
market like lead attenu growth meanwhil greater number
clinic trial enrol indic along sever expect new-to-market
lower-pr competitor figur expect cap growth opportun gmg
long-term horizon model peak gmg sale occur
rout
iv sc
iv sc
undisclos expect
similar soliri dose
phase expect start
phase expect start
mg/kg mg/kg qw
phase set initi
mg/kg qw
dose
current on-going develop
possibl compani may explor
current on-going develop
possibl compani may explor
nmosd demand high soliri price may limit factor recent
doc call soliri experienc non-experienc expert impli favor
skew toward util soliri relapse/refractori nmo patient ahead non-
complement-direct option clinic develop figur expect
abl leverag high-perform neurolog commerci capabl drive
strong launch though clinician regularli cite expect soliri price point
probabl result need cycl multipl option ahead use
rout adm dose
undisclos expect
similar soliri dose
phase expect initi
bridg ultomiri sc studi initi
file apporv expect later year
current pre-registr phase
top-line data present
iv sc
catalyst investor focu waiha soliri ip
fcrn waiha readout
oral proceed new soliri com patent eu
fcrn waiha trial initi
ultomiri phase adapt studi als- trial initi
fcrn gmg trial initi
ultomiri gmg phase trial initi
fcrn franchis potenti sourc upsid readout warm
autoimmun hemolyt anemia waiha well addit data pv studi
expect may disclos soon asset carri option
pathogen igg-medi diseas though competit space figur
believ investor expect construct outcom consid alxn decis
progress asset enthusiasm remain mute product trail
fcrn program market though target waiha lead indic
consult express high interest anti-fcrn class treatment
waiha see higher unmet need lack treatment option compar
hematolog indic current explor player
fcrn space despit lack data indic consult believ
base mechan action reason expect efficaci
waiha physician feedback suggest g/dl increas hb level would
warrant develop
igg auto-antibodi major driver destruct rbc waiha unlik
agglutinin diseas auto-antibodi usual igm remain bound
therefor fix complement major driver damag
warm diseas igg auto-antibodi remain bound promot
phagocytosi adcc complement-medi destruct also less
common waiha igg subclass dont activ complement
cascad reduc level circul igg could translat clinic benefit
though level reduct requir still unknown
hemolyt diseas fetu
newborn
on-going top-line data readout expect
plan
septemb soliri eu patent hear composit matter patent
soliri eu postpon origin februari date fundament
see rel limit impact valuat downsid vs upsid
note biosimilar risk around soliri ex-u remain stick point
mani investor speak believ posit outcom could attract sidelin
money wherea neg outcom like cement key lt overhang
continu view long-term brand competit biosimilar risk key governor
alexion multipl long compani remain extrem depend anti-
franchis soliri ultomiri transform and/or intern pipelin
develop meaning diversifi revenu stream continu key
element us subscrib sustain long-term upsid thesi alexion
rout
mg qd
subcutan infus
mg
mg iv follow
iv load dose plu
on-going phase mono tx treatment nave
add eculizumab data
expect monotherapi pt
transit phase subject
capston intiati eu
 vs soliri phase initi treatment-
phase complet phase expect enrol
phase expect initi earli
rout adm dose
iv sc
iv load follow sc
data expect earli pediatr
target full approv europ
acceler approv us anoth
pt fda full approv
phase clinic trial initi
current activ ahu
compani mention price
